Tapinarof cream compared with betamethasone cream for plaque psoriasis
Compares tapinarof cream with betamethasone cream in adults with mild to moderate plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
Key facts
- Where
- Islamabad, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07635043, who can take part
Where in Pakistan
- Pakistan institute of medical sciences(PIMS)Islamabad, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pakistan Institute of Medical Sciences
- Trial code
- NCT07635043
- Record updated
- 9 June 2026
- Original description
To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in IslamabadRead full original descriptionShow less
Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis
To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad
Inclusion: Age 18 years-65 years; Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity); Disease duration of at least 6 months; Willing and able to provide written informed consent; Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies).
Exclusion: Severe psoriasis (BSA >20% or requiring systemic therapy); Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis; Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment; Use of powerful topical corticosteroids within two weeks previously; Known hypersensitivity to Tapinarof or any of its excipients; History of malignancy or current active infection; Known hypersensitivity to betamethasone or Tapinarof; Pregnant and lactating mothers.